Oscar Health (OSCR) Earnings Date & Reports

Key Takeaways

• Oscar Health is scheduled to report second-quarter 2026 results before the market opens on Thursday, August 6, 2026.
• Analysts expect earnings per share of approximately $0.33 to $0.35, a dramatic swing from the loss of $0.89 per share reported in the same quarter last year.
• Consensus revenue estimates range from $4.71 billion to $4.83 billion, representing year-over-year growth of roughly 65% to 69%.
• The company's medical loss ratio (MLR) — the percentage of premiums spent on member medical care — and membership retention trends will be the most closely watched metrics.
• Oscar enters this earnings event with strong momentum: its stock has surged approximately 68% over the past 90 days, driven by a record-breaking first quarter.
• Full-year 2026 guidance calls for revenue of $18.7 billion to $19.0 billion and operating income between $250 million and $450 million, and any revision to these targets will move the stock.

Earnings Context and Why It Matters

Oscar Health's second-quarter 2026 earnings arrive at a pivotal moment for the technology-driven health insurer. The company is coming off a transformative first quarter in which it posted a record net profit of approximately $679 million, or $2.07 per diluted share, alongside a 53% year-over-year revenue jump to $4.65 billion. That performance, fueled by membership growth of 56% to roughly 3.2 million members and a medical loss ratio that improved by 490 basis points to 70.5%, reset investor expectations dramatically. Now the question is whether Oscar can sustain that trajectory. The Q2 report will offer the first major test of whether the company's pricing discipline, AI-driven cost efficiencies, and membership base are holding firm now that enhanced Affordable Care Act premium tax credits have expired — a policy shift that was expected to trigger gradual membership churn across the individual market.

Earnings Expectations

Wall Street's consensus points to a sharp year-over-year improvement in Oscar Health's bottom line. Analysts tracked by Yahoo Finance project second-quarter earnings per share of approximately $0.33 on average, while Zacks and TipRanks place the consensus closer to $0.34 to $0.35. That would mark a swing of roughly 138% from the $0.89 per-share loss Oscar reported in Q2 2025. On the top line, the consensus revenue estimate sits between $4.71 billion and $4.83 billion, depending on the data provider, which would represent roughly 65% to 69% growth from $2.86 billion a year ago.

Investors will be laser-focused on the company's medical loss ratio (MLR), which measures the share of premium revenue spent on medical claims. After posting an exceptionally low 70.5% MLR in the seasonally favorable first quarter, the company has guided to a full-year MLR range of 82.4% to 83.4%, with the ratio expected to rise steadily through year-end as members accumulate claims toward annual deductibles. Any significant deviation above the guided range would raise concerns about medical cost pressures. The SG&A (selling, general, and administrative) expense ratio — another critical efficiency gauge — is projected in the 15.8% to 16.3% range for the full year after hitting a company-record low of 15.2% in Q1.

Membership retention is another key variable. Oscar began the second quarter with roughly 3.0 million paid members. Management has cautioned that some gradual churn is expected now that enhanced premium tax credits under the American Rescue Plan Act (ARPA) have rolled off, returning attrition patterns closer to pre-ARPA levels. How membership trends are tracking against that expectation will shape the revenue outlook for the remainder of 2026.

Risk adjustment — the mechanism that transfers funds among insurers based on the health status of their members — remains a known wildcard. In Q1, risk adjustment ran at approximately 24% of direct premiums, above the roughly 20% normalized level Oscar expects for the full year. Updates on how risk adjustment is trending will be closely scrutinized.

AI Screener

For investors looking to identify opportunities beyond individual earnings reports, Tickeron's AI Screener offers a powerful AI-driven platform that helps traders and investors filter thousands of stocks and ETFs using customizable criteria including technical patterns, fundamentals, volatility metrics, and proprietary AI signals. Users can scan across industries, market capitalizations, and performance indicators to surface trade ideas, breakout candidates, and trending stocks far more efficiently than through manual screening. Whether you are seeking to confirm a thesis or discover new opportunities, the AI Screener can sharpen your market research workflow.

Market Reaction and Investor Sentiment

Sentiment heading into Oscar Health's Q2 report is cautiously optimistic but far from complacent. The stock has been on a tear, up roughly 68% over the trailing 90-day period and trading near $28 to $31 in recent sessions — well above its 200-day simple moving average of approximately $17.55. Barclays upgraded the stock to Overweight in June with a $35 price target, but the broader analyst consensus remains a Hold, with an average price target around $20 to $24, suggesting many analysts believe much of the good news is already priced in.

The Q2 report lands in a complex macro environment. Broader managed care stocks have been volatile as investors assess medical cost trends across the sector. Results from industry giants UnitedHealth and Elevance Health, which reported their own Q2 figures in mid-July, will have set some of the tone for how the market interprets Oscar's numbers. Additionally, geopolitical tensions and interest rate uncertainty have injected a risk-off undercurrent into equity markets, meaning Oscar will need a clean report — or better — to sustain its elevated valuation. The stock's reaction to its Q1 report in May was sharply positive, with shares jumping over 10% after the company delivered a massive EPS beat. A similar or even moderately positive surprise could reinforce the bullish narrative, while any cracks in membership or MLR trends could trigger a swift pullback given how far the stock has run.

Forward Outlook and Key Factors to Monitor

Beyond the headline numbers, Oscar Health's Q2 report will set the tone for the second half of 2026 and beyond. One of the most important signals will be whether management reaffirms, raises, or trims its full-year guidance. The current outlook calls for revenue of $18.7 billion to $19.0 billion, an MLR of 82.4% to 83.4%, and operating income of $250 million to $450 million. Given that Q1 alone produced $704 million in operating income, the implied trajectory for the remaining three quarters is materially lower — a seasonal pattern the market understands, but one that leaves little room for negative surprises.

Investors should also monitor the company's strategic initiatives. Oscar has been aggressively deploying artificial intelligence across operations, from real-time drug pricing tools that help members find lower-cost prescriptions to bilingual voice agents that streamline care navigation. These AI investments are credited with helping drive the SG&A ratio to historic lows, and any incremental detail on their financial impact will be welcomed.

The company's expansion into new distribution channels warrants attention. The recently launched Lucie Health Marketplace, a carrier-neutral shopping platform for consumers, brokers, and employers, and the industry initiative ICHRAx (Individual Coverage Health Reimbursement Arrangement exchange), aimed at streamlining the growing ICHRA employer market, both represent longer-term growth levers. While neither is likely to move the needle on Q2 results, updates on adoption trends and partnership progress could shape the multi-year growth narrative.

Finally, regulatory and policy developments remain an overhang for the entire individual health insurance market. With the enhanced ARPA subsidies now expired, the industry is watching enrollment patterns across all carriers. Oscar's management has expressed confidence that the individual market remains resilient, but real-world data on enrollment persistence and risk pool composition will accumulate through the second half of 2026. Oscar's scheduled Investor Day on September 16, 2026, adds another catalyst to the calendar — management is expected to share long-term strategic and financial targets that could further crystallize the investment thesis.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations